These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24407515)

  • 41. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.
    Shrivastav A; Bruce M; Jaksic D; Bader T; Seekallu S; Penner C; Nugent Z; Watson P; Murphy L
    Breast Cancer Res; 2014 May; 16(3):R49. PubMed ID: 24887419
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
    Mi W; Ye Q; Liu S; She QB
    Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth.
    Azoulay-Alfaguter I; Elya R; Avrahami L; Katz A; Eldar-Finkelman H
    Oncogene; 2015 Aug; 34(35):4613-23. PubMed ID: 25500539
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
    Lu PW; Li L; Wang F; Gu YT
    J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
    Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
    Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Involvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice.
    Ludka FK; Constantino LC; Dal-Cim T; Binder LB; Zomkowski A; Rodrigues AL; Tasca CI
    J Psychiatr Res; 2016 Nov; 82():50-7. PubMed ID: 27468164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.
    Wang Y; Zhang M; Wang Z; Guo W; Yang D
    Mol Carcinog; 2020 Oct; 59(10):1188-1198. PubMed ID: 32810332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 51. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
    Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
    Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine.
    Liu RJ; Fuchikami M; Dwyer JM; Lepack AE; Duman RS; Aghajanian GK
    Neuropsychopharmacology; 2013 Oct; 38(11):2268-77. PubMed ID: 23680942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
    Wu C; Luo J
    Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hesperidin induces apoptosis and triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of rapamycin and glycogen synthase kinase-3 beta signalling cascades in experimental colon carcinogenesis.
    Saiprasad G; Chitra P; Manikandan R; Sudhandiran G
    Eur J Cancer; 2014 Sep; 50(14):2489-507. PubMed ID: 25047426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
    Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
    Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
    Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
    Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling.
    Bénard L; Oh JG; Cacheux M; Lee A; Nonnenmacher M; Matasic DS; Kohlbrenner E; Kho C; Pavoine C; Hajjar RJ; Hulot JS
    Circulation; 2016 Apr; 133(15):1458-71; discussion 1471. PubMed ID: 26936863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of miR-224 down-regulation on SW80 cell proliferation and apoptosis and weakening of ADM drug resistance.
    Liang CQ; Fu YM; Liu ZY; Xing BR; Jin Y; Huang JL
    Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):5008-5016. PubMed ID: 29164556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.